Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedApr 12, 2026
DataAggregated Company Financials
Companies49
  • 7D1.6%
  • 3M9.6%
  • 1Y31.2%
  • YTD11.6%

In the last week, the Biotech industry is up 1.6%, with Swedish Orphan Biovitrum up 1.3%. In the same time, Hansa Biopharma was down 6.0%. This takes the industry's 12 month performance to a gain of 31%. As for the next few years, earnings are expected to grow by 26% per annum.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 12 Apr 2026SEK 232.3bSEK 38.5b-SEK 5,655,163,322.6917.9x-41.1x6x
Tue, 10 Mar 2026SEK 215.6bSEK 38.5b-SEK 5,719,509,052.6816.5x-37.7x5.6x
Thu, 05 Feb 2026SEK 211.6bSEK 38.2b-SEK 5,994,814,498.5127.3x-35.3x5.5x
Sat, 03 Jan 2026SEK 205.7bSEK 38.1b-SEK 556,456,830.2733.6x-369.7x5.4x
Mon, 01 Dec 2025SEK 209.5bSEK 38.1b-SEK 568,086,917.2132.3x-368.7x5.5x
Wed, 29 Oct 2025SEK 205.3bSEK 37.3b-SEK 1,169,432,533.9439.2x-175.6x5.5x
Fri, 26 Sep 2025SEK 194.4bSEK 36.4bSEK 3.0b31.2x64.2x5.3x
Sun, 24 Aug 2025SEK 196.3bSEK 35.9bSEK 2.7b29.2x73.8x5.5x
Tue, 22 Jul 2025SEK 184.7bSEK 35.9bSEK 2.8b28.2x66.6x5.1x
Thu, 19 Jun 2025SEK 183.3bSEK 35.2bSEK 2.2b28.7x82.2x5.2x
Sat, 17 May 2025SEK 192.5bSEK 33.9bSEK 1.2b34.5x160.3x5.7x
Mon, 14 Apr 2025SEK 169.4bSEK 33.7bSEK 750.2m28.3x225.7x5x
Wed, 12 Mar 2025SEK 187.7bSEK 33.7bSEK 582.0m32.2x322.5x5.6x
Fri, 07 Feb 2025SEK 225.0bSEK 33.7bSEK 289.8m57.7x776.5x6.7x
Sun, 05 Jan 2025SEK 221.9bSEK 33.0b-SEK 4,422,596,365.77162x-50.2x6.7x
Tue, 03 Dec 2024SEK 213.3bSEK 33.0b-SEK 4,445,760,324.15150.4x-48x6.5x
Thu, 31 Oct 2024SEK 222.9bSEK 33.2b-SEK 4,376,431,364.0833.3x-50.9x6.7x
Sat, 28 Sep 2024SEK 217.6bSEK 31.4b-SEK 5,542,929,538.9352.3x-39.3x6.9x
Mon, 26 Aug 2024SEK 209.5bSEK 31.4b-SEK 5,451,247,150.9849.4x-38.4x6.7x
Wed, 24 Jul 2024SEK 213.0bSEK 31.3b-SEK 5,447,085,607.3447.1x-39.1x6.8x
Fri, 21 Jun 2024SEK 193.1bSEK 30.6b-SEK 5,516,922,162.3239x-35x6.3x
Sun, 19 May 2024SEK 191.4bSEK 30.6b-SEK 5,507,222,037.7639.8x-34.7x6.3x
Tue, 16 Apr 2024SEK 179.8bSEK 29.8b-SEK 5,279,682,044.8864.7x-34.1x6x
Thu, 14 Mar 2024SEK 191.0bSEK 29.8b-SEK 5,636,578,997.8158.3x-33.9x6.4x
Sat, 10 Feb 2024SEK 176.3bSEK 29.6b-SEK 5,748,812,027.0660.4x-30.7x6x
Mon, 08 Jan 2024SEK 183.3bSEK 28.7b-SEK 1,198,220,759.0059.9x-153x6.4x
Wed, 06 Dec 2023SEK 174.6bSEK 28.7b-SEK 1,200,948,861.0058.8x-145.4x6.1x
Fri, 03 Nov 2023SEK 159.0bSEK 28.6b-SEK 1,304,911,737.0048.2x-121.8x5.5x
Sun, 01 Oct 2023SEK 161.8bSEK 27.4b-SEK 2,016,197,047.0051.3x-80.2x5.9x
Tue, 29 Aug 2023SEK 154.5bSEK 27.6b-SEK 1,825,740,116.0052.1x-84.6x5.6x
Thu, 27 Jul 2023SEK 155.3bSEK 27.5b-SEK 1,531,665,655.0058.5x-101.4x5.6x
Sat, 24 Jun 2023SEK 165.6bSEK 26.4b-SEK 1,312,079,266.0045.9x-126.2x6.3x
Mon, 22 May 2023SEK 175.1bSEK 26.3b-SEK 1,411,262,591.0046.7x-124.1x6.6x
Wed, 19 Apr 2023SEK 176.4bSEK 25.4b-SEK 2,026,956,582.0041.4x-87x6.9x
Price to Earnings Ratio

-87x


Total Market Cap: SEK 176.4bTotal Earnings: -SEK 2,026,956,582.00Total Revenue: SEK 25.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -47.4x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 15% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market4.42%
Healthcare2.34%
Biotech1.65%
Biotech1.65%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 406.201.3%
+SEK 1.9b		59.8%PE293.7x
BONEX Bonesupport HoldingSEK 229.807.3%
+SEK 1.0b		-21.2%PE107.9x
VITR VitrolifeSEK 96.704.3%
+SEK 534.9m		-36.3%PS3.8x
BIOG B BioGaiaSEK 120.002.7%
+SEK 313.6m		22.0%PE36.5x
MVIR MedivirSEK 2.5810.0%
+SEK 126.6m		106.4%PS163.4x

Latest News

SPRINT
SEK 3.66
Sprint Bioscience
7D
46.4%
1Y
470.1%
SOBI
SEK 406.20
Swedish Orphan Biovitrum
7D
1.3%
1Y
59.8%
BONEX
SEK 229.80
Bonesupport Holding
7D
7.3%
1Y
-21.2%
BIOA B
SEK 326.80
BioArctic
7D
-0.2%
1Y
98.5%

BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook

The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.
BIOSGN
SEK 10.00
Biosergen
7D
-71.4%
1Y
-66.2%
VITR
SEK 96.70
Vitrolife
7D
4.3%
1Y
-36.3%
BIOG B
SEK 120.00
BioGaia
7D
2.7%
1Y
22.0%

BIOG B: Downgrade And Extra Dividend Will Set Up Future Multiple Re Rating

Analysts have trimmed their stance on BioGaia with a lower SEK price target, reflecting more cautious views on the shares following a downgrade from SEB Equities and only slight adjustments to assumptions such as the discount rate and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the trimmed price target and modest changes to the discount rate and future P/E as leaving room for upside if execution on growth initiatives tracks current expectations.
VICO
SEK 9.97
Vicore Pharma Holding
7D
-2.1%
1Y
55.8%
HNSA
SEK 30.72
Hansa Biopharma
7D
-6.0%
1Y
40.4%

HNSA: U.S. Kidney Transplant Approval Pathway Will Drive Potential Upside

Analysts have adjusted their price target on Hansa Biopharma by SEK 8, reflecting updated views on the risk profile and near term commercial opportunity for imlifidase, including its potential positioning in kidney transplantation and autoimmune indications. Analyst Commentary Recent research shows a mix of optimism and caution around Hansa Biopharma, with views shaped by the commercial outlook for imlifidase in kidney transplantation and autoimmune indications, as well as how quickly the company can execute on its plans.
MVIR
SEK 2.58
Medivir
7D
10.0%
1Y
106.4%

Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects

Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?
CURAS
DKK 13.75
Curasight
7D
-2.8%
1Y
138.7%
XSPRAY
SEK 30.25
Xspray Pharma
7D
8.0%
1Y
1.7%
SUBGEN
SEK 0.13
Subgen AI
7D
-21.7%
1Y
n/a
CANTA
SEK 3.92
Cantargia
7D
-2.7%
1Y
201.5%
SANION
SEK 15.21
Saniona
7D
-7.0%
1Y
126.3%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%